Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals improvements in financial metrics, including reduced operating losses and cash burn due to restructuring. Although revenue decreased, optimistic guidance and strategic initiatives in AI and robotics present potential growth avenues. The Q&A section highlights positive reception of new services and potential revenue tailwinds. However, management's vague response on U.S. onshoring introduces some uncertainty. Overall, the positive elements, such as improved financial health and strategic growth plans, outweigh negatives, suggesting a likely positive stock price movement.
Key Financial Performance
Cell Engineering revenue (Q4 2025) $26 million, down 26% compared to Q4 2024. The decrease is primarily attributed to ongoing program rationalization as part of restructuring activities.
Cell Engineering revenue (Full Year 2025) $133 million, down from $174 million in 2024. Excluding noncash revenue impacts, it was $125 million in 2025 compared to $129 million in 2024. The decrease was driven by customer program rationalization related to restructuring.
Biosecurity business revenue (Q4 2025) $7 million.
Biosecurity business revenue (Full Year 2025) $37 million.
Cell Engineering R&D expense (Q4 2025) $28 million, a 44% decrease from $50 million in Q4 2024. The decrease was driven by restructuring efforts.
Cell Engineering R&D expense (Full Year 2025) $159 million, a 42% decrease from $272 million in 2024. The decrease included a $21 million shortfall obligation related to a strategic partnership with Google Cloud, which was settled for $14 million.
Cell Engineering G&A expense (Q4 2025) $12 million, a 40% decrease from $20 million in Q4 2024. The decrease was driven by restructuring efforts.
Cell Engineering G&A expense (Full Year 2025) $56 million, a 51% decrease from $115 million in 2024. The decrease was driven by restructuring efforts.
Cell Engineering segment operating loss (Q4 2025) $17 million, compared to a loss of $38 million in Q4 2024. The improvement was due to restructuring efforts.
Cell Engineering segment operating loss (Full Year 2025) $96 million, compared to a loss of $219 million in 2024. The improvement was due to restructuring efforts.
Biosecurity segment operating loss (Q4 2025) Improved by 60% compared to Q4 2024.
Biosecurity segment operating loss (Full Year 2025) Improved by 38% compared to 2024.
Total adjusted EBITDA (Q4 2025) Negative $36 million, improved from negative $57 million in Q4 2024. The improvement was due to restructuring efforts.
Total adjusted EBITDA (Full Year 2025) Negative $167 million, improved from negative $293 million in 2024. The improvement was due to restructuring efforts.
Cash burn (Q4 2025) $47 million, a 15% decrease from $55 million in Q4 2024. The decrease was a direct result of restructuring.
Cash burn (Full Year 2025) $171 million, a 55% decrease from $383 million in 2024. The decrease was a direct result of restructuring.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Autonomous Labs: The company is focusing on autonomous labs as a key technological and business priority for 2026. They plan to decommission traditional lab setups and consolidate operations into a single large autonomous lab in Boston. This lab will serve as a demonstration for potential customers like Merck and Pfizer. Additionally, they aim to commercialize autonomous labs by selling them to national labs, biopharma, and research universities. A $47 million deal with Pacific Northwest National Labs was highlighted as a key milestone.
Market Expansion in Biosecurity: The company is divesting its Biosecurity business to focus on autonomous labs. The Biosecurity unit will be spun off into a private entity, attracting investments from defense-focused investors. Ginkgo will retain a minority stake, allowing it to share in future upside while reallocating resources to autonomous labs.
Cost Efficiency: The company achieved a 55% reduction in cash burn from $383 million in 2024 to $171 million in 2025. This was attributed to restructuring efforts and a focus on cost efficiency. For 2026, cash burn is expected to be between $125 million and $150 million, reflecting continued cost discipline while investing in autonomous labs.
Revenue and Profitability: Cell Engineering revenue decreased from $174 million in 2024 to $133 million in 2025, primarily due to customer program rationalization. Adjusted EBITDA improved from negative $293 million in 2024 to negative $167 million in 2025, driven by restructuring efforts.
Strategic Shift to Autonomous Labs: The company is pivoting its focus to autonomous labs, which it sees as a transformative technology for biotechnology. This includes reallocating resources from other areas, such as the Biosecurity business, and emphasizing long-term investments in AI, robotics, and software to lead in this space.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Divestiture of Biosecurity Business: The company is divesting its Biosecurity business to focus on autonomous labs. This could lead to potential risks in terms of losing a revenue stream and the uncertainty of the success of the spun-off entity.
Restructuring and Cost Reductions: The company has significantly reduced its cash burn and R&D expenses, but this restructuring has led to a decrease in Cell Engineering revenue and ongoing program rationalization, which could impact future growth.
Focus on Autonomous Labs: The company is heavily investing in autonomous labs, which involves decommissioning traditional labs and transitioning to a single large autonomous lab. This shift carries risks related to execution, adoption by customers, and the ability to demonstrate its effectiveness to large biopharma companies.
Revenue Decline in Cell Engineering: Cell Engineering revenue decreased by 26% in Q4 2025 compared to Q4 2024, and by 23% for the full year. This decline is attributed to customer program rationalization and restructuring, which could impact the company's financial stability.
Dependence on Government and Pharma Contracts: The company relies heavily on contracts with government entities and large pharmaceutical companies. Any changes in these relationships or funding could adversely affect revenue.
Cash Burn and Financial Guidance: While cash burn has been reduced, the company is not providing revenue guidance for 2026, focusing instead on cash burn. This could create uncertainty for investors regarding future revenue performance.
Market Adoption of Autonomous Labs: The success of the autonomous labs initiative depends on market adoption by biopharma, research universities, and government labs. Failure to achieve significant adoption could impact the company's strategic objectives.
Competition in Lab Automation: The company faces competition in the lab automation space, which could impact its ability to capture market share and achieve its goals for autonomous labs.
Economic and Industry Downturns: The biotech sector downturn has already impacted the company's revenue and customer spending on outsourced R&D projects. Continued economic uncertainties could further affect performance.
Operational Challenges in Scaling Autonomous Labs: Scaling the autonomous lab system, including expanding from 50 to 100 RACs, involves significant operational challenges and risks related to execution and system reliability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Investment Focus: The company plans to focus its technological and business efforts on autonomous labs in 2026, emphasizing robotics, AI, and autonomy in laboratory research.
Biosecurity Business Divestiture: The company will divest its Biosecurity business to focus resources on autonomous labs. Ginkgo will retain a minority position in the divested entity, which will operate as a private biodefense company.
Demonstration of Autonomous Lab Capabilities: The company will systematically decommission traditional lab setups and consolidate R&D services into a single large autonomous lab in Boston to showcase its capabilities to potential customers.
Sales Goals for Autonomous Labs: The company aims to secure sales of autonomous labs to national labs, biopharma companies, and research universities, building on a $47 million deal with Pacific Northwest National Labs.
Cash Burn Guidance for 2026: The company expects cash burn to be in the range of $125 million to $150 million, reflecting investments in autonomous labs and cost efficiency measures.
Expansion of Autonomous Lab Infrastructure: The company plans to expand its autonomous lab in Boston from 50 to 100 RACs by the first half of 2026.
Cloud Lab Offering: The company will introduce a cloud lab service, allowing customers to outsource small-scale lab work directly to Ginkgo's autonomous lab.
AI Integration in Lab Operations: The company will continue to integrate AI, such as GPT-5, into lab operations to enable AI-driven experimental design and execution.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:With the planned expansion of RACs capacity from roughly 50 to 100 units at the Boston facility, how is this increased capacity expected to translate into 2026 revenue? Specifically, what portion of that contribution will be recurring in nature (e.g., software, operations, consumables) versus project-based services?
A:The RAC expansion aims to shift lab work onto the Nebula system, enabling services like data point service, cloud lab service, and Solution service. Solutions deals are typically multiyear R&D contracts with some repeatability, while Datapoints is becoming more repeat business as trust builds with partners. The cloud lab service is experimental but expected to generate repeat business. Additionally, selling the system to external entities involves an initial CapEx followed by ongoing service and software licenses, resembling a SaaS model.
Q:How should we think about U.S. onshoring of manufacturing as a potential tailwind to RACs revenue growth? What will Ginkgo need to do to maximize its share of this trend over the next couple of years?
A:Ginkgo sees potential in integrating RACs into manufacturing sites for quality control (QC) protocols. The systems can handle complex, multistep QC processes, which are currently done manually. Ginkgo is in discussions with customers about deploying automation in manufacturing sites, which could provide a tailwind for revenue growth.
Q:How is Ginkgo's Datapoints offering being received among customers? Are there any material tailwinds expected for this part of the business over the next 12 months?
A:The Datapoints offering is well-received, particularly in generating large datasets for bio AI models. Pharma companies are increasingly partnering with Ginkgo for proprietary data to train their ML teams. This trend is expected to create tailwinds for the business, as Ginkgo is positioned as a leader in providing datasets for large pharma and biotech ML teams.
Q:Is Ginkgo exploring any specific strategies, technologies, or methods to significantly enhance the production efficiency and scalability of RACs?
A:Ginkgo has made generational upgrades to RAC hardware to improve manufacturability, reducing components for easier scaling. Current production involves assembly in San Jose and Emeryville, California. While the company can scale decently with the current setup, it plans to invest in larger partners for manufacturing as demand grows.
Q:Review of Unclear Management Responses
A:Management appeared to avoid giving a direct answer to the question about U.S. onshoring of manufacturing as a tailwind for RACs revenue growth. While they discussed potential applications and ongoing discussions with customers, they did not provide specific strategies or quantifiable impacts, leaving the response somewhat vague.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO Director
COO CEO
COVID
Cash burn
Cell Engineering
Co COO
Co Founder
Engineering RD
Engineering noncash
Founder Co
Labs
RD expense
airport
announcement
biodefense
category lab
commitment term
cost efficiency
decrease Cash
defense sector
effort matter
entity
focus
investment biosecurity
investment lab
kid
laboratory research
obligation
program rationalization
rationalization restructuring
school
service tool
testing
tool investment
year spending
DNA Transcript
Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2025 Earnings Call Transcript
Positive2-27
The earnings call reveals improvements in financial metrics, including reduced operating losses and cash burn due to restructuring. Although revenue decreased, optimistic guidance and strategic initiatives in AI and robotics present potential growth avenues. The Q&A section highlights positive reception of new services and potential revenue tailwinds. However, management's vague response on U.S. onshoring introduces some uncertainty. Overall, the positive elements, such as improved financial health and strategic growth plans, outweigh negatives, suggesting a likely positive stock price movement.
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2025 Earnings Call Transcript
Unknown11-6
Despite strong cash reserves and cost management, the company faces challenges with declining revenues and increased losses in Cell Engineering. Positive aspects include restructuring efforts, optimism about government partnerships, and new product launches. However, the lack of significant revenue growth, increased operating losses, and the necessity to reset commitments with Google Cloud temper the outlook. The Q&A reveals optimism about AI and robotics, but the absence of immediate financial benefits suggests a neutral outlook for the stock price in the short term.
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call presents a mixed picture. While there are positives like improved EBITDA, cost reductions, and strong cash position, there are concerns about macroeconomic uncertainties, execution risks in new markets, and a reduction in biosecurity guidance. The Q&A section reveals potential in automation and RNA solutions but lacks clarity on timelines and geopolitical impacts. Overall, the mixed signals and lack of strong catalysts suggest a neutral stock price movement in the short term.
Earnings call transcript: Ginkgo Bioworks’ Q1 2025 revenue rises, stock slips
Positive5-6
The earnings call reveals positive financial performance with significant cost reductions, strong revenue growth in cell engineering, and improved EBITDA. The company has a solid cash position and no bank debt. Despite some uncertainties in the Q&A, the ARPA H contract and government projects provide revenue stability. The company is also exploring new opportunities in SaaS and automation, which could drive future growth. The overall sentiment is positive, with potential for stock price appreciation.
DNA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
